Connect with us

Business

Global WholeHealth Partners Corp (GWHP-OTC) Acquires Rights to Distribute & Sell a 2nd COVID-19 Vaccine – The Pfizer-BioNTech

Published

on

The Pfizer-BioNTech Was Found to be More Than 95% Effective Against Severe Disease or Death From Variants

Company Now Has the Rights to Distribute & Sell Both the Pfizer-BioNTech and J&J COVID-19 Vaccines; Respectively, the Most Effective and the Most Convenient Vaccines

Global WholeHealth Partners Corp. (OTC: GWHP), a company that offers one of the largest lines of COVID-19 tests including SARS-CoV-2 viruses and that states that its Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses, and that recently announced that they had acquired the rights to be able to distribute and sell Johnson & Johnson’s COVID-19 vaccine, today announced that they have now, also, acquired the rights to sell and distribute Pfizer’s vaccine.

As with the Johnson & Johnson, the Pfizer-BioNTech 8K was filed on June 10, 2021, for the J&J rights and Pfizer-BioNTech, the Company has also filed an 8K on June 16, 2021, stating that “Effective June 4, 2021, Global WholeHealth Partners Corporation (the ‘Company’) was granted the rights from Nunzia Pharmaceutical Inc. (‘Nunzia’) to distribute and sell the Pfizer-BioNTech COVID-19 Vaccine. The Company will serve as a broker for Nunzia and follow the same sales order processing as used by Nunzia in connection with the distribution and sale of the Vaccine.”[1]

On December 11, 2020, Pfizer became the first COVID-19 vaccine to gain an FDA EUA, after the company reported positive clinical trial data, which included news that the vaccine was up to 95% effective at preventing symptomatic disease. According to Yale Medicine[2], they said that: “(Pfizer’s vaccine has a) 95% efficacy in preventing COVID-19 in those without prior infection. The researchers report that the vaccine was equally effective across a variety of different types of people and variables, including age, gender, race, ethnicity, and body mass index (BMI)—or presence of other medical conditions. In clinical trials, the vaccine was 100% effective at preventing severe disease… and in early May, the Pfizer-BioNTech vaccine was found to be more than 95% effective against severe disease or death from the variants first detected in the United Kingdom (B.1.1.7, or the Alpha variant) and South Africa (B.1.351, or the Beta variant) in two studies based on real-world use of the vaccine. While the efficacy against infection varied between the two studies, both also showed the vaccine provides strong protection.”

The Company already offers one of the largest lines of COVID-19 tests, including the strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein.

Mr. Charles Strongo, the CEO and Chairman of WholeHealth Products Inc., said: “Global will now have both J&J’s extremely convenient 1-shot vaccine, and we now have the rights to the Pfizer-BioNTech vaccine, which is generally considered the highest efficacy.”

About Global WholeHealth Partners Corp

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. The Company has the capacity to deliver hundreds of thousands of tests, and can ramp up to 1 million tests per day and the Company presently has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA, many of which are Approved for OTC use, and 15 POC products approved by the CLIA WAIVED FDA.

For more information please go to:www.gwhpcorp.com

Sales: 714-392-3423, Sales@gwhpcorp.com

Media: Charles Strongo 714-392-9752

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Continue Reading
Advertisement

Business

WynCore Offers Warehouse Management System Optimization Services to Businesses

Published

on

By

With all the changes in the delivery and ordering processes, your company needs a customized approach to upgrading WMS to optimize results. Your confident choice to provide these services is WynCore. We provide customized warehouse management system modifications for Manhattan Software. For more information, get in touch with WynCore today to speak with our software developers about your warehouse management software upgrade services and customization needs by calling us at 866-996-2673.

With over 50 years of combined experience in the industry, we are known as a leader in WMS configurations, providing you with a full host of services including: design and implementation, QA Testing, customized maintenance, support and training. We can craft your WMS optimization plan in a cost-effective package to suit your business.

We know that running a business smoothly and efficiently directly affects your bottom line. Our expert software developers design a customized modification or upgrade to assist you in operating your warehouse flawlessly. From minor tweaks and adjustments to your WMS or complete redesign, WynCore consultants craft your ideal solution.

In addition, we are proud to note that our developers and project management teams are experts in both Agile and Waterfall methodologies and well versed in DEV-OPS and in training your staff.

Our support to you does not stop at the end of your WMS customization services. Our project management and global support team provides assistance whenever you needed it to help minimize disruptions with any arising issue after completing your WMS modifications.

Your investment in optimizing begins with your choice of WyCore. We know the WMS business inside and out and offer a team of experts that  can provide all you want within the budget and timeline that you need to meet. From a small adjustment or modification to a major overhaul our consultants provide the plan, implantation and support for your custom needs. Why delay? Speak with our software developers about your warehouse management software upgrade services and customization needs by calling us at 866-996-2673.

Continue Reading

Business

Purchase Superior COVID-19 Diagnostic Testing Kits And Personal Protective Equipment Online from Global WholeHealth Partners

Published

on

By

Searching for and finding in stock PPE supplies and COVID-19 diagnostic testing kits online is easy when you shop Global WholeHealth Partners. As COVID-19 cases increase as a result of the Delta Variant, we continue to source and supply these in demand products. Even in the midst of the pandemic, we are able to supply these products as a result of our standing partnerships with key players in the industry.

As vaccines are making their way to millions of Americans and people worldwide, we are hopeful that COVID-19 cases will begin to decline. However, the use of PPE supplies remains high as domestic and international travel increases as well as more and more retail stores and restaurants begin to open.

We all can do our part to help slow the spread of COVID-19 by social distancing where we can, staying quarantined when we are sick, and using PPE supplies when leaving the house. Masks wearing is required in most public indoor places such as shopping malls, grocery stores and restaurants and often times negative COVID-19 tests are required for travel.

Browse our medical supply page today to view current inventory and offerings. Remember, GWHP Corp sources and supplies the best PPE supplies and COVID-19 diagnostic testing kits. We are proud to be able to source and supply these in demand products in wholesale quantities during these trying times. Get in touch with us today by calling 877-568-4947.

About Global WholeHealth Partners OTC (GWHP)
GWHP provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines that detect between 1 – 1 ½ hours and Rapid Diagnostic Testing (RDT) Serum Plasma that detect between 15 -20 minutes, which predict diseases ahead of its industry competitors. Our focus is encompassing, improving, and preserving the quality of life by providing fast, adequate and accurate test results to prompt early treatment and cut cost of accumulated diseases all over the world. By so doing, GWHP has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. MISSION GWHP is committed to building long term shareholder value through the vertical integration of proven, well established business that effectively and efficiently control disease outbreak and significantly reducing health care costs. VISION Our vision is to lead the industry in infectious disease diagnostics and provide molecular solutions that lessen the time to diagnose medical results, empower healthcare professionals to make better diagnostic decisions, and lower healthcare costs.

Continue Reading

Business

GWHP Corp Sources Wholesale PPE Supplies and COVID 19 Testing Kits In The Age of Coronavirus and Rising COVID-19 Cases

Published

on

By

With many states and countries still facing lockdowns, social distancing measures and required use of PPE gear, Global WholeHeath Partners recognizes that demand is still high for COVID-19 diagnostic testing kits and PPE supplies. We are proud to announce that our standing relationships and partnerships with key players in the industry enable us to source and supply large quantities of these in demand products. Visit our medical supply page online today to view current offerings. We are happy to provide fast fulfillment times on your wholesale orders as well.

We all can do our part to help slow the spread of COVID-19 by social distancing where we can, staying quarantined when we are sick, and using PPE supplies when leaving the house. Masks wearing is required in most public indoor places such as shopping malls, grocery stores and restaurants and often times negative COVID-19 tests are required for travel.

Even as the Pfizer and Moderna vaccine are making their way to millions of people across the globe, continued use of PPE supplies will help slow the spread of the virus so we can end this pandemic.

To place your wholesale order of PPE supplies or COVID-19 diagnostic testing kits get in touch with us today. Global WholeHealth Partners stands committed to sourcing these in demand products for interested parties in wholesale capacities. Visit our medical supply page to view current offerings and get in touch with us to place your wholesale order, call 877-568-4947.

About Global WholeHealth Partners OTC (GWHP)
GWHP provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines that detect between 1 – 1 ½ hours and Rapid Diagnostic Testing (RDT) Serum Plasma that detect between 15 -20 minutes, which predict diseases ahead of its industry competitors. Our focus is encompassing, improving, and preserving the quality of life by providing fast, adequate and accurate test results to prompt early treatment and cut cost of accumulated diseases all over the world. By so doing, GWHP has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. MISSION GWHP is committed to building long term shareholder value through the vertical integration of proven, well established business that effectively and efficiently control disease outbreak and significantly reducing health care costs. VISION Our vision is to lead the industry in infectious disease diagnostics and provide molecular solutions that lessen the time to diagnose medical results, empower healthcare professionals to make better diagnostic decisions, and lower healthcare costs.

Continue Reading

Trending